Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is 2.67% higher on its value in year-to-date trading and has touched a low of $99.06 and a high of $148.06 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The JAZZ stock was last observed hovering at around $124.99 in the last trading session, with the day’s gains setting it 1.45%.
Currently trading at $126.44, the stock is -6.06% and -4.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 1.16% at the moment leaves the stock 6.57% off its SMA200. JAZZ registered 6.27% gain for a year compared to 6-month gain of 13.49%. The firm has a 50-day simple moving average (SMA 50) of $132.2766 and a 200-day simple moving average (SMA200) of $118.64755.
The stock witnessed a -9.00% loss in the last 1 month and extending the period to 3 months gives it a 2.82%, and is -3.39% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.48% over the week and 3.07% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $7.68B and $4.07B in sales. Current P/E ratio is 14.54 and Fwd P/E is 5.48. Profit margin for the company is 13.77%. Distance from 52-week low is 27.64% and -14.60% from its 52-week high. The company has generated returns on investments over the last 12 months (5.48%).
The EPS is expected to grow by 12.01% this year
698.0 institutions hold shares in Jazz Pharmaceuticals plc (JAZZ), with institutional investors hold 102.92% of the company’s shares. The shares outstanding are 60.63M, and float is at 57.97M with Short Float at 7.80%. Institutions hold 99.75% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.1103 of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.7735 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9448 and valued at over $264.75 million, while CAPITAL WORLD INVESTORS holds 3.2117 of the shares totaling 2.02 million with a market value of $215.55 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
Jazz Pharmaceuticals plc disclosed in a document filed with the SEC on Mar 10 ’25 that Iannone Robert (EVP, Global Head of R&D & CMO) sold a total of 2,403 shares of the company’s common stock. The trade occurred on Mar 10 ’25 and was made at $138.41 per share for $0.33 million. Following the transaction, the insider now directly holds 79621.0 shares of the JAZZ stock.
Still, SEC filings show that on Mar 10 ’25, Carr Patricia (SVP, Chief Accounting Officer) disposed off 1,140 shares at an average price of $137.81 for $0.16 million. The insider now directly holds 7,012 shares of Jazz Pharmaceuticals plc (JAZZ).
